The ulcerative colitis market will be rocked in the coming few years as new agents and biosimilar competitors come to the fore. Until now, UC therapeutic treatment has been ruled by anti-tumor necrosis factor (TNF) blockbusters Humira, Simponi and Remicade.
Established products for the treatment of UC will suffer in the coming years because of pressure from biosimilars and sales...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
